

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**同方康泰產業集團有限公司**  
**Tongfang Kontafarma Holdings Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1312)**

**PROFIT WARNING**

This announcement is made by Tongfang Kontafarma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Group that based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022, the Group is expected to record a consolidated net loss for the six months ended 30 June 2022 of approximately HK\$28.4 million to HK\$42.7 million as compared to the consolidated net loss of approximately HK\$73.2 million for the corresponding period in 2021.

The narrowing of loss of the Group was mainly attributable to (i) the increase in revenue and gross profit in the pharmaceutical business segment as the Group has not experienced failure of a major product supplier in making timely delivery of production materials in the first half of 2022, whereas the Group encountered such failure in the first half of 2021 which led to negative impact on its sale in respect of such period; (ii) the increase in revenue and gross profit from the fitness business in Singapore as a result of the social distancing restrictions being uplifted since the end of April 2022 which, to a certain extent, offset the decrease in royalty fee income in Taiwan region caused by the outbreak of pandemic; and (iii) no further impairment on the goodwill having been made for the fitness business segment of the Group in the first half of 2022, as compared to the impairment loss on goodwill of approximately HK\$46.4 million recognised in the corresponding period of 2021, and such positive impact offset the increase in the expected credit loss on receivables for the fitness business. The Group would continue to monitor closely the evolving market environment in the second half of 2022 so as to adopt appropriate business strategies from time to time.

The information contained in this announcement is based on the latest assessment by the management of the Company according to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 and taking into account the latest assessment on the performance of the aforesaid business segments and may be subject to amendments. Therefore, the actual results of the Group for the six months ended 30 June 2022 may differ from the information contained in this announcement.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board of  
**Tongfang Kontafarma Holdings Limited**  
**Bai Pingyan**  
*Chairman*

Hong Kong, 19 August 2022

*As at the date of this announcement, the Board comprises four executive directors, namely Mr. Bai Pingyan (Chairman), Mr. Chai Hongjie, Mr. Huang Yu (President) and Mr. Jiang Chaowen (Chief Executive Officer) and three independent non-executive directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.*